Oncolytic viruses constitute a promising therapeutic approach for treatment of cancer. These viruses selectively replicate in tumor cells and effectively kill these cells without harming normal cells. Selectively engineered, the virus not only destructs the target tumor cell, but also stimulates the host’s anti-tumor immune response.
This case study describes a robust upstream process and downstream process for oncolytic adenovirus production. Purity of final samples meets regulatory requirements.